TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19220279
Drug: Cetilistat 300
Normalized name: Cetilistat
DrugBank: Cetilistat (DB06586)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cetilistat 300 mg t.i.d. (n = 9)
Study: 19220279
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg t.i.d. (n = 9)
Study: 11561263
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL bupivacaine 0.25% plus fentanyl 2.5 microg/mL (group BF)
Study: 11561263
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL bupivacaine 0.25% (group B)
Study: 11561263
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL bupivacaine 0.125% plus fentanyl 2.5 microg/mL (group DBF)
Study: 29703289
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (ocular bandage gel 4 times a day for 14 days and bandage contact lens)
Study: 29703289
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (ocular bandage gel 4 times a day for 14 days)
Study: 16076697
Drug: Sequential, dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential, dose-dense epirubicin plus docetaxel
Study: 11920355
Drug: 7.5% icodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% icodextrin solution (Extraneal)
Study: 8529496
Drug: Chromium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium supplementation (220 micrograms elemental chromium daily for 90 days)
Study: 1760827
Drug: verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 120 sustained-release
Study: 1760827
Drug: combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy (ISDN + verapamil)
Study: 7161777
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 7.5 to 25 mg oral or intramuscular
Study: 29565948
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg SR-nitrite, BID
Study: 29565948
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg SR-nitrite, BID
Study: 12595814
Drug: Selective phosphodiesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective phosphodiesterase type-5 inhibitors
Study: 10893703
Drug: Racemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic ketamine 0.3 mg/kg
Study: 10893703
Drug: (R)-ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-ketamine 0.5 mg/kg
Study: 10893703
Drug: (S)-ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-ketamine 0.15 mg/kg
Study: 1486186
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily in the morning
Study: 6489418
Drug: 22 registered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 registered pharmaceutical specialities
Study: 17663104
Drug: Routine obstetric
Normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine obstetric treatment with catgut embedding at Zusanli (ST 36) and Shangjuxu (ST 37)
Study: 17663104
Drug: Routine obstetric
Normalized name: chlorhexidine gluconate Topical Cream [Hibitane Obstetric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine obstetric treatment
Study: 12017421
Drug: Pramlintide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide (all doses)
Study: 9890379
Drug: IV Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Ondansetron (4 mg)
Study: 1646490
Drug: Subcutaneous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low molecular weight heparin (CY 216)
Study: 1646490
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous unfractionated heparin
Study: 6752926
Drug: Antrafenine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antrafenine (up to 1200 mg daily)
Study: 6752926
Drug: Paracetamol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (up to 4 g daily)
Study: 29130845
Drug: Restrictive red-cell
Normalized name: Bos taurus red blood cell preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive red-cell transfusion strategy (transfuse if hemoglobin <7.5 g/dL)
Study: 29130845
Drug: Liberal red-cell
Normalized name: Bos taurus red blood cell preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal red-cell transfusion strategy (transfuse if hemoglobin <9.5 g/dL in operating room or ICU, <8.5 g/dL in non-ICU ward)
Study: 23975474
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (PC) using the Dáder method
Study: 17513805
Drug: Six cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of epirubicin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 and granulocyte colony‐stimulating factor on days 3 through 10 (ED+G), every 21 days
Study: 17513805
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of epirubicin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 and granulocyte colony‐stimulating factor on days 3 through 10 (ED+G), every 21 days
Study: 17513805
Drug: Six cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of ED+G
Study: 17513805
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of ED+G
Study: 15208047
Drug: Lower-dose formulation
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose formulation of Depo-Provera (104 mg/0.65 mL)
Study: 15208047
Drug: Original formulation
Normalized name: Zegerid (Original Formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original formulation of Depo-Provera (150 mg/mL)
Study: 26538423
Drug: High-dose hemithoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hemithoracic radiotherapy
Study: 26538423
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy and extrapleural pneumonectomy
Study: 23744726
Drug: Exenatide plus
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide plus metformin
Study: 21295742
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones 120 mg/d
Study: 21295742
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones 80 mg/d
Study: 21295742
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (both doses)
Study: 7588455
Drug: Concomitant b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant b.i.d. medications
Study: 7588455
Drug: Thrice-daily (t.i.d.)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily (t.i.d.) medications
Study: 7588455
Drug: Four times
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times daily (q.i.d.) medications
Study: 27500463
Drug: Sativex® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sativex® treatment
Study: 26158157
Drug: Pyridoxine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine (60 mg/d)
Study: 23020850
Drug: Belly dance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belly dance (16 weeks, twice a week)
Study: 19053980
Drug: 3.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g/d prebiotic
Study: 19053980
Drug: 7 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/d prebiotic
Study: 19053980
Drug: 7 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/d placebo
Study: 15068719
Drug: Continuous veno-venous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous veno-venous hemofiltration (CVVH) combined with conventional therapy
Study: 9850013
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg transbuccal melatonin
Study: 2531117
Drug: Single-dose spectinomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spectinomycin (TRO: 2 g intramuscularly)
Study: 2531117
Drug: Aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous procaine penicillin G (APPG: 4.8 x 10(6) units) plus 1 g of probenecid
Study: 2531117
Drug: Aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous procaine penicillin G (APPG)
Study: 2531117
Drug: Single-dose spectinomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose spectinomycin (TRO)
Study: 21699484
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl 25 mg once daily
Study: 21699484
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl 75 mg once daily
Study: 21699484
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl 150 mg once daily
Study: 15380912
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention (3 x 125 ml, 2.38 MJ/day)
Study: 11808987
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy for 3 weeks
Study: 9756115
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron therapy (total dose 1050 mg over seven consecutive dialysis sessions and supplemental monthly doses)
Study: 25559730
Drug: Probiotic administration
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic administration (twice daily, initiated within 10 days of burn until wound closure)
Study: 25559730
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration (twice daily, initiated within 10 days of burn until wound closure)
Study: 21768631
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment in a cast
Study: 16274054
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with Photosense, 0.05 mg/kg, performed on day 3 after administration, using a laser at 675 nm and a light dose of 120 J/cm2
Study: 12420854
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (2 g/200 mg)
Study: 9452274
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA), 500 mg, twice daily for 12 weeks
Study: 791564
Drug: Methyldopa administered
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa administered once at bedtime (HS)
Study: 791564
Drug: Methyldopa administered
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa administered three times daily (TID)
Study: 25300706
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR 2.0‐3.5)
Study: 18077494
Drug: 5 min
Normalized name: Creon 5 Minimicrospheres Delayed-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 min treatment
Study: 18077494
Drug: 2 min
Normalized name: Accu-Clear 2 Minute Pregnancy Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 min treatment
Study: 10919681
Drug: CFC pressurized
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC pressurized metered dose inhaler (pMDI; Ventolin)
Study: 8816621
Drug: Luteal support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal support with oral E2 (2 mg three times daily) and vaginal P (100 mg twice daily) starting on the day of retrieval and ET
Study: 4050728
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment (30 mg iron as ferrous sulfate given before a meal)
Study: 25840585
Drug: Probiotic lozenge
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenge containing two strains of Lactobacillus reuteri, taken once daily for 17 months.
Study: 25840585
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge without active bacteria, taken once daily for 17 months.
Study: 22219013
Drug: FOLFIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI plus cetuximab (400 mg/m2 day 1, followed by 250 mg/m2 weekly)
Study: 22219013
Drug: FOLFIRI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI plus bevacizumab (5 mg/kg every 2 weeks)
Study: 2058557
Drug: Sotalol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (1.5 mg/kg over 10 minutes)
Study: 6352951
Drug: Weekly blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly blood pressure checks
Study: 30678553
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Pembrolizumab plus chemotherapy)
Study: 19228151
Drug: Withdrawal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal therapy followed by neurologist (group A)
Study: 19228151
Drug: Withdrawal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal therapy followed by primary care physician (group B)
Study: 16297576
Drug: Soy-rich diet
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-rich diet (25 g soy protein, >50 mg/day isoflavones)
Study: 15330019
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) combined with intermittent pneumatic compression
Study: 15330019
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) combined with graduated compression stockings
Study: 11200857
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention (eight sessions) followed by outpatient treatment
Study: 11200857
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who dropped out of outpatient treatment
Study: 9294113
Drug: Alendronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5 to 20 mg/d)
Study: 8112205
Drug: DHEP plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEP plaster (180 mg, applied b.i.d. for 14 days)
Study: 3106210
Drug: High fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fat load (3 g/kg/day)
Study: 3106210
Drug: Medium fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium fat dosage (1.5 g/kg/day)
Study: 19595361
Drug: Net decrease
Normalized name: [(im-Bzl)-D-His6,Pro9-NEt]-gonadotropin releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Net decrease in T-wave amplitude during reperfusion therapy
Study: 9598491
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral sertraline
Study: 9598491
Drug: Chronic open
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic open label treatment with sertraline
Study: 7873461
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus pamidronate (Aredia) 45 mg intravenously every 3 weeks
Study: 7873461
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus pamidronate (Aredia)
Study: 3285485
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 120 mg/d plus diethylstilbestrol (DES) 0.1 to 3 mg/d
Study: 3285485
Drug: Diethylstilbestrol (DES)
Normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylstilbestrol (DES) 0.1 to 3 mg/d
Study: 11557459
Drug: IDV-RTV 800-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDV-RTV 800-100 mg
Study: 11557459
Drug: IDV-RTV 800-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDV-RTV 800-200 mg
Study: 11557459
Drug: IDV-RTV 400-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDV-RTV 400-400 mg
Study: 11557459
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of IDV with RTV 100 mg
Study: 11557459
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of IDV with RTV 200 mg
Study: 11557459
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of IDV with RTV 400 mg
Study: 31257177
Drug: Trastuzumab duocarmazine
Normalized name: Trastuzumab duocarmazine
DrugBank: Trastuzumab duocarmazine (DB16342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab duocarmazine (1.2 mg/kg recommended phase 2 dose)
Study: 29328779
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment settings
Study: 24904204
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (control group).
Study: 9935020
Drug: Captopril 6.25
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 6.25 mg increasing to 50 mg t.d.s. after intravenous streptokinase
Study: 7561799
Drug: Oral brivudin
Normalized name: Brivudine
DrugBank: Brivudine (DB03312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral brivudin (125 mg tablet every 6 hours for 5 days)
Study: 7561799
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (10 mg/kg infused over 1 hour every 8 hours for 5 days)
Study: 7561799
Drug: Oral brivudin
Normalized name: Brivudine
DrugBank: Brivudine (DB03312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral brivudin
Study: 2222030
Drug: Percutaneous needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous needle aspiration with drugs (metronidazole, diloxanide, chloroquine)
Study: 2222030
Drug: Drugs alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs alone (metronidazole, diloxanide, chloroquine)
Study: 2222030
Drug: Drugs alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs alone (non-aspirated group)
Study: 31285082
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m2, carboplatin AUC 6 mg/mL/min, and bevacizumab 15 mg/kg every 21 days until disease progression, complete remission, or limiting toxicity.
Study: 31285082
Drug: Paclitaxel, carboplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, carboplatin, and bevacizumab treatment
Study: 29195602
Drug: Erythrocytapheresis (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythrocytapheresis (treatment group)
Study: 29195602
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment by plasmapheresis (control group)
Study: 25644578
Drug: 0.20 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 ml local anaesthetic per mm² cross-sectional nerve area (starting volume)
Study: 25644578
Drug: 0.02 ml.mm(‐2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 ml.mm(‐2) reduction in local anaesthetic volume if surgical anaesthesia was adequate
Study: 21647577
Drug: Dextroamphetamine (AMP)
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (AMP) 10 mg and 20 mg
Study: 21647577
Drug: Δ(9)-tetrahydrocannabinol (THC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ(9)-tetrahydrocannabinol (THC) 7.5 mg and 15 mg
Study: 27687347
Drug: Sugammadex (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (4 mg/kg)
Study: 17449580
Drug: 3.2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 g/d CLA
Study: 17449580
Drug: 6.4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4 g/d CLA
Study: 17449580
Drug: Placebo (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 g safflower oil/d)
Study: 8186134
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% cream applied twice daily for 1 week
Study: 8186134
Drug: Clotrimazole 1%
Normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole 1% cream applied twice daily for 4 weeks
Study: 29068831
Drug: Balanced colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced colloid solution
Study: 26630142
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus immunosuppressive therapy (immunosuppression group) for 3 years
Study: 11119091
Drug: Bladder infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder infusion before trial of voiding (ToV)
Study: 8814495
Drug: Erythropoietin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin therapy (45‐60 U/kg, three times a week)
Study: 8814495
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (haemodialysis patients without erythropoietin treatment)
Study: 1415040
Drug: Whole-cell pertussis-component
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell pertussis-component diphtheria-tetanus-pertussis vaccine (DTP)
Study: 1415040
Drug: Acellular pertussis-component
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis-component diphtheria-tetanus-pertussis vaccine (APDT)
Study: 29661413
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (1 μg kg-1)
Study: 29661413
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine via atomiser (1 μg kg-1)
Study: 29661413
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine by drops (1 μg kg-1)